-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$9.6739.74% Upside
Recursion Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. has been rated by research analysts at Needham, KeyBanc, Jefferies in the past 90 days.